Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2019 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
October 03, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

-Top-line results expected in second half of 2020- SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company...
October 01, 2019 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

First preclinical data for newly-announced IL4I1 immuno-oncology programPreclinical data for orally bioavailable CD73 inhibitor CB-708 SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) --...
September 29, 2019 10:30 ET | Source: Calithera Biosciences, Inc.

New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
September 28, 2019 02:30 ET | Source: Calithera Biosciences, Inc.

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of...
September 26, 2019 18:05 ET | Source: Calithera Biosciences, Inc.

Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
September 25, 2019 08:05 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
September 03, 2019 09:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

-Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted...
August 28, 2019 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
August 08, 2019 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences,...